TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Xtant Medical Holdings ( (XTNT) ).
On August 1, 2025, Xtant Medical Holdings announced the election of Abhinav Jain and Tyler Lipschultz to its Board of Directors, with immediate effect. Jain, with a background in investment management and pharmaceuticals, and Lipschultz, with extensive experience in orthopaedics and spine industries, bring valuable expertise to the board. This change follows a significant stock purchase agreement earlier in 2025, where Nantahala Capital Management acquired a substantial share of Xtant’s common stock. This board restructuring aligns with Nantahala’s interests and is expected to impact the company’s governance positively.
The most recent analyst rating on (XTNT) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Xtant Medical Holdings stock, see the XTNT Stock Forecast page.
Spark’s Take on XTNT Stock
According to Spark, TipRanks’ AI Analyst, XTNT is a Neutral.
Xtant Medical’s overall score is driven primarily by its strong revenue growth and strategic advancements, which are tempered by ongoing profitability and cash flow challenges. Technical indicators and valuation metrics suggest caution, while the earnings call provided a positive outlook despite some operational challenges.
To see Spark’s full report on XTNT stock, click here.
More about Xtant Medical Holdings
Xtant Medical Holdings operates in the medical technology industry, focusing on products related to orthopaedics, spine, and biologics. The company is involved in providing surgical solutions and has a market focus on spinal disorders.
Average Trading Volume: 185,686
Technical Sentiment Signal: Strong Sell
Current Market Cap: $78.02M
For detailed information about XTNT stock, go to TipRanks’ Stock Analysis page.